Boston Scientific Enters Definitive Deal To Acquire Bolt Medical; Transaction Consists Of Upfront Payment Of $443M For The 74% Stake Not Yet Owned
Boston Scientific Enters Definitive Deal To Acquire Bolt Medical; Transaction Consists Of Upfront Payment Of $443M For The 74% Stake Not Yet Owned
As a strategic investor in Bolt Medical, Boston Scientific has an equity stake of approximately 26 percent. As a result, the transaction consists of an upfront payment of approximately $443 million for the 74 percent stake not yet owned and up to $221 million upon achievement of certain regulatory milestones.
作为Bolt Medical的战略投资者，波士顿科学拥有约26%的股权。因此，交易包括大约$44300万的预付款，以收购尚未持有的74%的股权，以及在达到某些监管里程碑后最高可支付$22100万。
Boston Scientific anticipates the transaction to be completed in the first half of 2025, subject to customary closing conditions. On an adjusted basis, the company expects the transaction to be slightly dilutive to adjusted earnings per share (EPS) in 2025, and to offset via internal cost efficiencies and trade-offs.
波士顿科学预计该交易将在2025年上半年完成，前提是满足常规的成交条件。经调整后，公司预计该交易将在2025年对每股收益（EPS）产生轻微稀释，并通过内部成本效益和权衡进行抵消。
